Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B lands $40.5mm for Amplyx; adds $8.7mm

Executive Summary

Over five years after closing its two-tranche $1.5mm Series A, Amplyx Pharmaceuticals Inc. brought in $40.5mm in Series B financing led by RiverVest Venture Partners, which was joined by New Enterprise Associates, BioMed Ventures, and individuals. A representative from RiverVest and NEA take board seats. Funds will support Phase I (expected to commence next year) and II trials of APX001 for candidiasis, invasive aspergillosis, and rare molds. Concurrent with the financing Amplyx announced changes to its management team.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies